A telephone call was held between His Royal Highness Prince Salman bin Hamad Al Khalifa, Crown Prince and Prime Minister and Vertex Pharmaceuticals CEO and President Dr Reshma Kewalramani yesterday.
HRH Prince Salman highlighted the kingdom’s medical milestone in successfully completing the treatment of the world’s first sickle cell disease patient outside the United States with Casgevy (exagamglogene autotemcel), a CRISPR-based gene-editing therapy using bone marrow transplantation technology.
He reaffirmed the importance of strengthening the kingdom’s partnership with Vertex Pharmaceuticals to promote future opportunities that further support Bahrain’s health sector.
HRH Prince Salman noted the kingdom’s commitment to enhancing co-operation with leading international specialised medical institutions, ensuring Bahrain remains at the forefront of scientific advancements.
HRH the Crown Prince and Prime Minister emphasised the importance of integrating cutting-edge treatments into healthcare and rehabilitation services for Bahrainis, underscoring this as a top priority.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts.
Top stories for today:
HEALTHCARE VOW: HRH Prince Salman visits sickle cell patient after his pioneering treatment
New medical opportunities
Tourism ‘vital for economic growth’
&uuid=(email))